ConductScience.org, home

Library / Trial comparisons

Zoster-022 GSK1437173A Group vs Zoster-022 Placebo Group: Number of Subjects With Fatal Serious Adverse Events (SAEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.06130.05590.0672wilsonClinicalTrials.gov
Risk in group 20.0660.06040.0721wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.00475-0.01290.00338newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9280.8171.05logClinicalTrials.gov
Odds ratio, group 1 over group 20.9230.8061.06logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Zoster-022 GSK1437173A Group than on Zoster-022 Placebo Group211from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Zoster-022 GSK1437173A GroupSubjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.4266,950OG000ClinicalTrials.gov
Group 2Zoster-022 Placebo GroupSubjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.4596,950OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Subjects With Fatal Serious Adverse Events (SAEs)ClinicalTrials.gov
Description
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
ClinicalTrials.gov
Time frameDuring the entire study period (3 to 5 year period following Day 0)ClinicalTrials.gov
PopulationThis analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleStudy to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and OlderClinicalTrials.gov
NCT numberNCT01165229ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsHerpes Zoster, Herpes Zoster VaccineClinicalTrials.gov
InterventionsHerpes Zoster Vaccine GSK1437173A, PlaceboClinicalTrials.gov
Lead sponsorGlaxoSmithKlineClinicalTrials.gov
Results first posted2017-11-20ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01165229?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.